Alamar Biosciences 3Q 2026: Revenue $33.5M, Net loss $13.3M, EPS $(0.19) — 10-Q Summary

What happened

Alamar Biosciences reported third-quarter 2026 revenue of $33.5M, up 68% from a year earlier, while its net loss widened to $13.3M from $8M. Diluted earnings per share, meaning profit or loss allocated to each share, was a loss of 0.19, compared with a loss of 0.69 a year earlier.

Confirmed

Global impact / market context

Revenue growth alongside a wider net loss shows that higher sales have not yet translated into a smaller overall loss. If consumables demand and sales prices continue to rise, revenue could grow further, but costs and spending will determine whether that growth improves the company’s financial results.

Analyst inference

The article reports that consumables revenue grew 79%, supported by a larger installed instrument base, higher demand and higher selling prices. It also says Alamar plans to seek FDA marketing authorization for ARGO HT/DX in 2027, but does not report approval or expected financial returns.

Confirmed

What to watch

1. Check whether upcoming results show revenue growth continuing and whether the net loss narrows; together, these figures indicate whether growing sales are improving overall financial performance. Analyst inference
2. Watch for the company’s planned 2027 FDA submission for ARGO HT/DX. Submission is a request for review, not authorization to market the product. Proposed
3. Track consumables revenue and the number of installed ARGO HT instruments, because sustained growth in both could support recurring sales, while weaker demand could limit that channel. Analyst inference

Evidence

• Original source link unavailable